학술논문
Post-exposure treatments for Ebola and Marburg virus infections
Document Type
Report
Author abstract
Author abstract
Source
Nature Reviews Drug Discovery. June 2018, Vol. 17 Issue 6, p413, 22 p.
Subject
Language
English
ISSN
1474-1776
Abstract
Author(s): Robert W. Cross [1, 2]; Chad E. Mire [1, 2]; Heinz Feldmann [3]; Thomas W. Geisbert (corresponding author) [1, 2] Introduction Among viruses that cause haemorrhagic fever, members of [...]
The filoviruses -- Ebola virus and Marburg virus -- cause lethal haemorrhagic fever in humans and non-human primates (NHPs). Filoviruses present a global health threat both as naturally acquired diseases and as potential agents of bioterrorism. In the recent 2013-2016 outbreak of Ebola virus, the most promising therapies for post-exposure use with demonstrated efficacy in the gold-standard NHP models of filovirus disease were unable to show statistically significant protection in patients infected with Ebola virus. This Review briefly discusses these failures and what has been learned from these experiences, and summarizes the current status of post-exposure medical countermeasures in development, including antibodies, small interfering RNA and small molecules. We outline how our current knowledge could be applied to the identification of novel interventions and ways to use interventions more effectively.
The filoviruses -- Ebola virus and Marburg virus -- cause lethal haemorrhagic fever in humans and non-human primates (NHPs). Filoviruses present a global health threat both as naturally acquired diseases and as potential agents of bioterrorism. In the recent 2013-2016 outbreak of Ebola virus, the most promising therapies for post-exposure use with demonstrated efficacy in the gold-standard NHP models of filovirus disease were unable to show statistically significant protection in patients infected with Ebola virus. This Review briefly discusses these failures and what has been learned from these experiences, and summarizes the current status of post-exposure medical countermeasures in development, including antibodies, small interfering RNA and small molecules. We outline how our current knowledge could be applied to the identification of novel interventions and ways to use interventions more effectively.